BioCardia is a regenerative medicine company developing therapeutics for cardiovascular diseases. Co.'s main therapeutic candidate is the CardiAMP Cell Therapy System, which provides an autologous bone marrow derived cell therapy for the treatment of two clinical indications: heart failure that develops after a heart attack and chronic myocardial ischemia. Co.'s second therapeutic candidate is the CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived allogenic off the shelf cell therapy from a donor. Co. has three enabling device product lines: CardiAMP cell processing system, Helix biotherapeutic delivery system; and Morph vascular access product line. The BCDA stock yearly return is shown above.
The yearly return on the BCDA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2014 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the BCDA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|